Why the study?
Do Biolimus A9-eluting stents and other DES provide safe and effective outcomes (MACE and stent thrombosis) in patients with coronary artery disease in a real-world setting?
Do Biolimus A9-eluting stents and other DES provide safe and effective outcomes (MACE and stent thrombosis) in patients with coronary artery disease in a real-world setting?
Answers are grounded in this paper and cite their sources.
Biolimus A9-eluting stents and other DES demonstrate good 1- and 2-year clinical safety and efficacy with low MACE rates in a real-world all-comers setting.
New generation DES are effectively used in all spectrum of coronary artery diseases (CAD) and are replacing earlier DES and BMS. Biolimus A9™-eluting stent is a new generation DES containing the anti-proliferative drug biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia. A retrospective data analysis was done in patients treated with DES, with a major share of Biolimus A9™ (BA9™) drug-eluting stents (DES) at Bombay Hospital, Mumbai. A total of 158 patients with 219 lesions were treated with DES, comprising Biolimus A9-eluting stent and others and the major adverse cardiac events (MACE) rate and stent thrombosis (ST) at 1, 6, 12 months and 24 months were analyzed. Mace rate was 3.16% for average follow-up of 19 months. There were 3 cases of ST (2 of acute and 1 of subacute onset) and one non-cardiac death reported during this time. This retrospective data demonstrates good one- and two-year clinical safety and efficacy of DES, especially of BioMatrix stents in real world setting.
No takes yet. Share an insight, caveat, or question.
Goyal et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: